Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

Jithendra Kini Bailur, Graham Pawelec, Sigrid Hatse, Barbara Brouwers, Ann Smeets, Patrick Neven, Annouschka Laenen, Hans Wildiers, Christopher Shipp, Jithendra Kini Bailur, Graham Pawelec, Sigrid Hatse, Barbara Brouwers, Ann Smeets, Patrick Neven, Annouschka Laenen, Hans Wildiers, Christopher Shipp

Abstract

Background: Effective therapeutic management of elderly patients with cancer, on an individual basis, remains a clinical challenge. Here, we identify novel biomarkers to assess elderly patients (≥70 years of age) with breast cancer undergoing treatment with or without chemotherapy.

Methods: We performed comprehensive geriatric assessment and measured markers sensitive to alteration in ageing, including leukocyte telomere length, CMV serostatus, levels of circulating growth factors and cytokines, and immune profiling of T cell and myeloid populations in blood before and at 3 months and 12 months after initiation of therapy, using flow cytometry.

Results: We observed changes in immune profiles over time that were specific to patients receiving chemotherapy; these patients had elevated CD4+ T effector memory re-expressing CD45RA (TEMRA) cells and relatively lower CD8+ central memory cells at 3 months, with normalized levels after 12 months. Patients' baseline immune profiles correlated with markers such as telomere length, cytomegalovirus (CMV) serostatus and levels of circulating cytokines. We also identified correlations between baseline immune profile and geriatric assessment, i.e. more frail patients had higher levels of granulocytic cells but lower levels of cells with suppressor phenotypes including myeloid-derived suppressor cells and regulatory T cells, although none of the examined immune populations correlated with chronological age. Importantly, immune profiles prior to therapy predicted unexpected hospitalizations in patients receiving chemotherapy.

Conclusion: These findings suggest that immune profiling may represent a novel complementary approach to more accurately assess the global health status of the elderly patient with breast cancer and select the most appropriate individual treatment option.

Trial registration: ClinicalTrials.gov, NCT00849758 . Registered on 20 February 2009.

Keywords: Blood leukocyte; Breast cancer; Chemotherapy; Clinical frailty; Immune profile.

Figures

Fig. 1
Fig. 1
Estimated mean immune biomarker levels (with 95% confidence intervals) in patients undergoing chemotherapy (green lines) or not having chemotherapy (blue lines) at baseline, 3 months and 12 months after starting therapy. Relative to patients not receiving chemotherapy (control group (CG)), those receiving chemotherapy (chemotherapy group (CTG)) had a lower ratio of CD4:CD8 T cells at 3 months before partial normalization (a), while there were relative increases in CTG patients at 3 months followed by normalization at 12 months in CD8 + CD27-CD28– (b) CD4+ T effector memory re-expressing CD45RA (TEMRA) memory cells (c) and CD15+ granulocytic cells (d). There were relative decreases in CD8+ central memory cells (e) and CD8+ CD27+ CD28+ T cells (f) in the CTG at 3 months before normalization. Chemo chemotherapy group

References

    1. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) Lancet Oncol. 2012;13(4):e148–160. doi: 10.1016/S1470-2045(11)70383-7.
    1. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101–15. doi: 10.1016/S1470-2045(07)70378-9.
    1. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. doi: 10.1200/JCO.2013.54.8347.
    1. Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, Lago LD, Repetto L, Ring A, Wildiers H. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol. 2014;5(2):204–18. doi: 10.1016/j.jgo.2013.09.001.
    1. Muller L, Pawelec G. As we age: Does slippage of quality control in the immune system lead to collateral damage? Ageing Res Rev. 2015;23(Pt A):116–23. doi: 10.1016/j.arr.2015.01.005.
    1. Onyema OO, Decoster L, Njemini R, Forti LN, Bautmans I, De Waele M, Mets T. Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer. Anticancer Res. 2015;35(3):1481–9.
    1. Bailur JK, Gueckel B, Derhovanessian E, Pawelec G. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. 2015;17:34. doi: 10.1186/s13058-015-0541-z.
    1. Bailur JK, Derhovanessian E, Gueckel B, Pawelec G. Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer. 2015;3:45. doi: 10.1186/s40425-015-0090-0.
    1. Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O et al. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget. 2016;7(21):29977-88.
    1. Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S, Langenaeken C, et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013;24(5):1306–12. doi: 10.1093/annonc/mds619.
    1. Alam I, Goldeck D, Larbi A, Pawelec G. Flow cytometric lymphocyte subset analysis using material from frozen whole blood. J Immunoassay Immunochem. 2012;33(2):128–39. doi: 10.1080/15321819.2011.604370.
    1. Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev. 2014;259(1):88–102. doi: 10.1111/imr.12160.
    1. Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol. 2016;39:23–9. doi: 10.1016/j.coi.2015.12.003.
    1. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104–18. doi: 10.1158/0008-5472.CAN-13-1545.
    1. Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P. Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunol Immunother. 2015;64(1):83–9. doi: 10.1007/s00262-014-1576-1.
    1. Baniyash M. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol Immunother. 2016;65(7):857–67. doi: 10.1007/s00262-016-1849-y.
    1. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15(3):1046–51. doi: 10.1158/1078-0432.CCR-08-1507.
    1. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013;4:271. doi: 10.3389/fimmu.2013.00271.
    1. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67(20):10019–26. doi: 10.1158/0008-5472.CAN-07-2354.
    1. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9. doi: 10.1093/gerona/glu057.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する